Abstract
Malignant gliomas are the most common primary central nervous system tumors, and the most aggressive and frequent form is the World Health Organization (WHO) grade IV astrocytoma, or glioblastoma. The standard treatment of glioblastoma consists of aggressive resection, radiation therapy, and concomitant and adjuvant treatment with the DNAalkylating agent temozolomide. Despite treatment, the prognosis is dismal for the vast majority of glioblastoma patients, with over 90% of patients succumbing to the disease within 5 years and a median survival of just over 1 year after diagnosis. There is clearly a great need for the development of therapeutic agents targeting pathways driving glioma malignancy, including cell proliferation, invasion, survival, as well as angiogenesis and pathways leading to resistance to cytotoxic therapies. Identification and validation of biomarkers predictive of response to therapy for patient stratification is an essential component of the development of targeted therapies. Comprehensive molecular characterization of tumor tissues is becoming prevalent, and developing approaches to integrate and bring this knowledge to the clinic will fuel the incorporation of targeted therapy in the management of malignant gliomas.
Keywords: Glioblastoma, glioma, targeted therapy, biomarkers, cell signaling, molecular profiling, clinical trials, chemotherapy
Current Signal Transduction Therapy
Title:Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy Recent advances in Molecular Characterization of Glioblastoma
Volume: 8 Issue: 1
Author(s): Ana C. deCarvalho, Norman L. Lehman and Tom Mikkelsen
Affiliation:
Keywords: Glioblastoma, glioma, targeted therapy, biomarkers, cell signaling, molecular profiling, clinical trials, chemotherapy
Abstract: Malignant gliomas are the most common primary central nervous system tumors, and the most aggressive and frequent form is the World Health Organization (WHO) grade IV astrocytoma, or glioblastoma. The standard treatment of glioblastoma consists of aggressive resection, radiation therapy, and concomitant and adjuvant treatment with the DNAalkylating agent temozolomide. Despite treatment, the prognosis is dismal for the vast majority of glioblastoma patients, with over 90% of patients succumbing to the disease within 5 years and a median survival of just over 1 year after diagnosis. There is clearly a great need for the development of therapeutic agents targeting pathways driving glioma malignancy, including cell proliferation, invasion, survival, as well as angiogenesis and pathways leading to resistance to cytotoxic therapies. Identification and validation of biomarkers predictive of response to therapy for patient stratification is an essential component of the development of targeted therapies. Comprehensive molecular characterization of tumor tissues is becoming prevalent, and developing approaches to integrate and bring this knowledge to the clinic will fuel the incorporation of targeted therapy in the management of malignant gliomas.
Export Options
About this article
Cite this article as:
C. deCarvalho Ana, L. Lehman Norman and Mikkelsen Tom, Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy Recent advances in Molecular Characterization of Glioblastoma, Current Signal Transduction Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574362411308010003
DOI https://dx.doi.org/10.2174/1574362411308010003 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnology Platforms in Diagnosis and Treatment of Primary Brain Tumors
Recent Patents on Nanotechnology Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Cellular Oxidative/Antioxidant Balance in γ-Irradiated Brain: An Update
Mini-Reviews in Medicinal Chemistry Protective Role of Natural Products in Glioblastoma Multiforme: A Focus on Nitric Oxide Pathway
Current Medicinal Chemistry The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Translational Medicine is Promoting Cross-talk of Interdiscipline)
Anti-Cancer Agents in Medicinal Chemistry Magnetic Resonance Diffusion Tensor Imaging and Diffusion Tensor Tractography in the Evaluation of Congenital and Acquired Diseases of the Pediatric Visual System
Current Pediatric Reviews Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors
Current Topics in Medicinal Chemistry Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents
Current Drug Targets - Immune, Endocrine & Metabolic Disorders MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Current Pharmaceutical Design Hedgehog Signaling and Urological Cancers
Current Drug Targets